Director/PDMR Shareholding
Moly Mines Ltd.
€0.00
07:46 20/03/24
9 March 2020
SEGRO plc (the Company)
Dealing by Director
On 9 March 2020 , the Company was notified of the following transaction by a Director. Following the transaction, the Director's beneficial holding is as follows:
Director | Date of purchase | Number of shares purchased | Purchase price per share (pence) | Resultant beneficial holding |
Mary Barnard | 5 March 2020 | 2,258 | 880.78 | 5,662 |
3,404 | 876.59 |
The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation (2014/596/EU) in relation to the transaction listed above is set out below:
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||
a)
| Name | Mary Barnard | |||||||||
2. | Reason for the notification | ||||||||||
a)
| Position/status
| Non-Executive Director | |||||||||
b)
| Initial notification /Amendment
| Initial | |||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a)
| Name
| SEGRO plc | |||||||||
b)
| LEI | 213800XC35KGM9NFC641 | |||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 10 pence each | |||||||||
b)
| Nature of the transaction | Purchase of shares | |||||||||
c)
| Price(s) and volume(s) |
| |||||||||
d)
| Aggregated information | N/A | |||||||||
e)
| Date of the transaction
| 5 March 2020 | |||||||||
f)
| Place of the transaction
| London Stock Exchange (XLON) |
Elizabeth Blease
General Counsel and Group Company Secretary
020 7451 9083
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.